OraSure Technologies (NASDAQ:OSUR) Rating Lowered to Hold at StockNews.com

OraSure Technologies (NASDAQ:OSUR) was downgraded by stock analysts at StockNews.com from a “buy” rating to a “hold” rating in a research report issued on Saturday.

OraSure Technologies Price Performance

OSUR stock opened at $3.80 on Friday. The business has a 50 day simple moving average of $3.80 and a 200-day simple moving average of $4.03. The firm has a market capitalization of $283.44 million, a PE ratio of 25.33 and a beta of 0.05. OraSure Technologies has a 1 year low of $3.52 and a 1 year high of $8.04.

Institutional Trading of OraSure Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of OSUR. D. E. Shaw & Co. Inc. increased its position in OraSure Technologies by 180.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,517,541 shares of the medical instruments supplier’s stock worth $5,478,000 after purchasing an additional 976,475 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of OraSure Technologies by 23.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock valued at $10,016,000 after buying an additional 521,400 shares during the period. Archon Capital Management LLC increased its holdings in shares of OraSure Technologies by 145.1% during the 4th quarter. Archon Capital Management LLC now owns 827,777 shares of the medical instruments supplier’s stock worth $2,988,000 after buying an additional 490,034 shares during the last quarter. Peapod Lane Capital LLC purchased a new stake in shares of OraSure Technologies during the 4th quarter valued at approximately $1,730,000. Finally, Systematic Financial Management LP lifted its holdings in OraSure Technologies by 33.7% in the fourth quarter. Systematic Financial Management LP now owns 1,673,609 shares of the medical instruments supplier’s stock valued at $6,042,000 after acquiring an additional 421,497 shares during the last quarter. 93.50% of the stock is owned by institutional investors and hedge funds.

About OraSure Technologies

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.